NuView Life Sciences is a privately held company whose mission is the discovery, development and commercialization of a new generation of diagnostic molecular imaging probes and biomarkers. NuView is a leader in the development of molecular imaging biomarkers with multiple promising commercial Positron Emission Technology (PET) and Single Photon Emission Computerized Technology (SPECT) compounds already in animal and human pre Food and Drug Administration (FDA) trials.

NuView’s pipeline of innovative biomarkers has the potential to earlier detect and better define the treatment of heart disease and many cancers. This is possible because our biomarkers are designed to improve the detection of first-stage pathological changes before disease symptoms or structural changes occur; subsequently, allowing for earlier treatment choices for improving patient outcomes.

We're NuView, a company with a "new view" on how to improve and personalize diagnosis and treatment of human disease.